Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180307 · ClinicalTrials.gov registry record · Phase 3
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
A Phase 3 study, sponsored by On Target Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT03180307: Completed Phase 3 study, sponsored by On Target Laboratories.
NCT03180307 is a Phase 3 study that has completed, run by On Target Laboratories. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03180307, a Phase 3 study, has completed, sponsored by On Target Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.
Interventions
- PROCEDURE laparotomy
- DRUG OTL38
- DEVICE near infrared camera imaging system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2020-10-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03180307
The ClinicalTrials.gov registry entry for NCT03180307 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is On Target Laboratories, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laparotomy is the first listed.
NCT03180307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03180307 about?
NCT03180307 is a clinical study titled "OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer". This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.
What is the current status of trial NCT03180307?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2018-01-26. Estimated completion is 2020-10-16.
What interventions are being tested in trial NCT03180307?
The interventions under investigation include: laparotomy (PROCEDURE), OTL38 (DRUG), near infrared camera imaging system (DEVICE).
Who is sponsoring clinical trial NCT03180307?
This trial is sponsored by On Target Laboratories, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.